# Increasing Ozempic Dose Linked to Lower Heart Risk Than Switching to Mounjaro
People taking Ozempic who increase their dose show lower heart risk compared to those who switch to Mounjaro, according to recent research. The study examined outcomes for patients already stabilized on Ozempic who needed to adjust their treatment.
When patients increased their Ozempic dose, they maintained better cardiovascular protection than those who switched to Mounjaro as an alternative. The research suggests that continuing with a higher Ozempic dose preserves the drug's heart benefits more effectively than transitioning between GLP-1 receptor agonists.
Both Ozempic and Mounjaro belong to the GLP-1 receptor agonist class of medications. These drugs work by mimicking glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite. Beyond diabetes management, both have demonstrated cardiovascular benefits in clinical trials, making them popular for weight loss and metabolic health.
The distinction between the two medications matters for patients requiring dose adjustments. Ozempic, which contains semaglutide, has an established track record for cardiovascular protection. Mounjaro, which contains tirzepatide, combines GLP-1 and GIP receptor agonism, offering a different mechanism.
The findings have implications for treatment planning. Patients currently stable on Ozempic who need enhanced effects may benefit from dose escalation rather than switching medications. This approach appears to maintain the cardiovascular advantages that led many people to start the drug initially.
Researchers from Healthline analyzed this comparison to help clinicians make informed decisions about medication adjustments. The research emphasizes that medication switches involve trade-offs beyond efficacy, including potential loss of established cardiovascular protection.
These results support individualized treatment approaches. Patients and providers should we